Ignite Creation Date:
2024-07-17 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06495177
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-07-02
Brief Title:
European Survey of Cardiovascular Disease Prevention Diabetes and Chronic Kidney Disease EUROASPIRE VI
Sponsor:
European Society of Cardiology
Organization:
European Society of Cardiology
Study Overview
Official Title:
European Survey of Cardiovascular Disease Prevention Diabetes and Chronic Kidney Disease
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EUROASPIRE VI
Brief Summary:
The goal of this observational study is to provide a unique European picture of preventive action by cardiologists other specialists and primary care physicians looking after patients with coronary heart disease CHD individuals at high cardiovascular disease risk and all those with hypertension dyslipidaemia including familial hypercholesterolaemia diabetes and dysglycaemia and chronic kidney disease CKD and determine whether the European guidelines on cardiovascular disease prevention hypertension lipids diabetes and chronic kidney disease are being followed
Detailed Description:
EUROASPIRE is a multicentre European study in coronary patients and individuals at high risk of developing cardiovascular disease CVD describing their management through lifestyle and use of drug therapies and providing an objective assessment of clinical implementation of current scientific knowledge Five EUROASPIRE surveys have been carried out by the European Society of Cardiology so far EUROASPIRE I in 1995-1997 in nine countries EUROASPIRE II in 1999- 2000 in 15 countries EUROASPIRE III in 2006-2009 in 22 countries EUROASPIRE IV in 2012-2015 in 26 countries and EUROASPIRE V in 2016-2018 in 27 countries
This sixth EUROASPIRE survey will investigate the cardiometabolic and renal continuum in both secondary and primary cardiovascular disease prevention in 2023-2025 under the auspices of the European Society of Cardiology Global Registries And Surveys Programme GRASP As in the previous EUROASPIRE surveys this survey will be focused on hospital patients with CHD with and without diabetes mellitus and apparently healthy individuals in primary care at high risk hypertension dyslipidaemia diabetes of developing CVD
This sixth EUROASPIRE survey will investigate the cardiometabolic and renal continuum in both secondary and primary cardiovascular disease prevention in 2023-2025 under the auspices of the European Society of Cardiology Global Registries And Surveys Programme GRASP As in the previous EUROASPIRE surveys this survey will be focused on hospital patients with CHD with and without diabetes mellitus and apparently healthy individuals in primary care at high risk hypertension dyslipidaemia diabetes of developing CVD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None